Orris

Hey buddy

Hey! How's it going? What can I help you with today?

Hey, can you explain me about the congenital heart disease, sinotic and asinotic, ASD, VSD, PDA, TOF? Rheumatic fever and rheumatic heart disease, congenital cardiac failure, hematological conditions like, uh, congenital hemophilia, thalassemia. Anemia, leukemia, idiopathic thrombocytopenic purpura, Hodgkin's and non-Hodgkin's lymphoma.

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a thorough breakdown of all the conditions you asked about, drawn from Robbins Pathology, Rosen's Emergency Medicine, Morgan & Mikhail's Clinical Anesthesiology, and Robbins & Kumar Basic Pathology.

CONGENITAL HEART DISEASE (CHD)

Congenital heart disease refers to structural abnormalities of the heart or great vessels that are present at birth. They are broadly classified into acyanotic (left-to-right shunts, no cyanosis early) and cyanotic (right-to-left shunts, cyanosis is present).

ACYANOTIC (Left-to-Right Shunts)

In these defects, oxygenated blood from the left side is shunted back to the lungs. Cyanosis is not an early feature. However, if left uncorrected, prolonged pulmonary overcirculation causes pulmonary hypertension - eventually reversing the shunt to right-to-left (producing cyanosis). This reversal is called Eisenmenger syndrome, at which point defects are considered irreversible.

Atrial Septal Defect (ASD)

Definition: An abnormal, fixed opening in the atrial septum allowing unrestricted blood flow between atria.
Types:
  • Ostium secundum (90%): Most common. Near the fossa ovalis. Smooth-walled defect due to insufficient growth of septum secundum.
  • Ostium primum (5%): At the lowest part of atrial septum. Associated with mitral and tricuspid valve abnormalities.
  • Sinus venosus (~5%): Near the superior vena cava; commonly associated with anomalous pulmonary venous drainage.
Note: A patent foramen ovale (PFO) is different from an ASD - in PFO, the septa are adequate in size to cover the foramen but remain unsealed in ~20% of people. PFO rarely causes symptoms but can allow paradoxical embolism.
Hemodynamics: Blood flows left atrium → right atrium → increased right-sided volume load → right atrial and ventricular dilation, right ventricular hypertrophy, pulmonary artery dilation.
Clinical features:
  • Often asymptomatic and detected incidentally on murmur auscultation
  • Large ASDs: dyspnea on feeding, poor weight gain, frequent respiratory infections
  • Characteristic finding: widely split and fixed S2 (doesn't vary with respiration)
  • Chest X-ray: cardiomegaly, right atrial/ventricular enlargement, prominent pulmonary artery, increased pulmonary vascular markings
  • ECG: right axis deviation, right ventricular hypertrophy (RVH)
  • Unlike VSDs, uncomplicated ASDs carry a low risk of bacterial endocarditis (low turbulence)
Management: Transcatheter septal occlusion devices (preferred today) or open-heart surgical patch repair. Antiplatelet therapy for 6 months post-device placement.

Ventricular Septal Defect (VSD)

Definition: An opening in the ventricular septum. VSD is the most common congenital heart defect overall.
Hemodynamics: Left ventricle (high pressure) → right ventricle → increased pulmonary blood flow AND pressure. Causes both increased pulmonary volume and pulmonary hypertension over time.
Clinical features:
  • Small VSDs ("restrictive"): may close spontaneously; produce a loud harsh pansystolic murmur (blood squirting through small hole)
  • Large VSDs: signs of congestive heart failure (CHF) - poor feeding, tachypnea, failure to thrive
  • Higher risk of infective endocarditis compared to ASD (due to turbulent jet)
  • Eisenmenger syndrome with late cyanosis if uncorrected
Management: Small VSDs often close spontaneously. Large ones require surgical or catheter-based closure.

Patent Ductus Arteriosus (PDA)

Definition: Persistence of the ductus arteriosus - a fetal vascular channel connecting the pulmonary artery to the aorta - beyond the first few weeks of life.
Fetal role: The ductus normally allows blood to bypass the non-functional fetal lungs (right → left shunt in fetal life). After birth, rising oxygen levels and falling prostaglandins cause it to close, usually within 1-2 days.
Hemodynamics post-birth: Aorta (high pressure) → pulmonary artery = left-to-right shunt. Increases pulmonary blood flow and volume load on the left side of the heart.
Clinical features:
  • Continuous "machinery" murmur, best heard at left infraclavicular area
  • Wide pulse pressure, bounding pulses
  • Associated with prematurity and maternal rubella infection
  • Can lead to pulmonary hypertension and Eisenmenger if not corrected
Management:
  • Premature neonates: indomethacin (prostaglandin inhibitor) induces closure
  • Full-term infants/children: surgical ligation or transcatheter coil/device occlusion
  • In ductal-dependent lesions (e.g., pulmonary atresia), the PDA must be kept open with prostaglandin E1 (PGE1) infusion to sustain life until surgery

CYANOTIC (Right-to-Left Shunts)

In these defects, deoxygenated blood enters the systemic circulation directly, causing cyanosis from birth or shortly after.

Tetralogy of Fallot (TOF)

Definition: The most common cyanotic CHD beyond infancy. Results from a single embryologic defect - failure of the subpulmonic conus to expand - causing four abnormalities:
  1. Right ventricular outflow tract obstruction (RVOTO / pulmonic stenosis)
  2. Large, unrestrictive, misaligned VSD
  3. Overriding aorta (sits above both ventricles)
  4. Right ventricular hypertrophy (secondary to RVOTO)
Hemodynamics: RVOTO forces deoxygenated RV blood across the VSD into the left ventricle and out to the body. The pulmonary vasculature is protected from pressure overload (unlike in acyanotic defects), so pulmonary hypertension is rare. However, patients develop polycythemia (compensatory, due to chronic hypoxia), clubbing, and risk of infective endocarditis.
Clinical features:
  • Degree of cyanosis depends on severity of RVOTO
  • "Pink TOF" (mild RVOTO): acyanotic at rest
  • Severe RVOTO: profound cyanosis within days of birth; PGE1 needed to maintain pulmonary flow via PDA
  • "Tet spells": paroxysmal cyanotic attacks triggered by crying, feeding, or exertion. SVR falls → more RV blood shunts right-to-left → acute severe hypoxia + metabolic acidosis
  • Systolic ejection murmur along left sternal border
  • Clubbing and polycythemia
  • Chest X-ray: "boot-shaped heart" (concave pulmonary artery segment, upturned apex), decreased pulmonary vascular markings, normal heart size
  • Right-sided aortic arch in 25%
  • ECG: RVH, right axis deviation
Management of tet spell: Knee-chest position, oxygen, IV morphine (reduces infundibular spasm), IV fluids, phenylephrine (raises SVR). Definitive treatment is complete surgical repair (patch VSD + relieve RVOTO).

Other Cyanotic Defects (for context)

DefectKey Feature
Transposition of Great ArteriesAorta from RV, pulmonary artery from LV - two parallel circuits, not compatible with life unless VSD/PDA/ASD present. Emergency surgery
Pulmonary atresiaNo pulmonary valve; PDA-dependent for lung blood flow
Tricuspid atresiaNo tricuspid valve; always associated with ASD
Truncus arteriosusSingle vessel from both ventricles

RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE

Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease; Fuster and Hurst's The Heart, 15th Ed.

Rheumatic Fever (RF)

Definition: An acute, immunologically mediated, multisystem inflammatory disease occurring 2-3 weeks after Group A Streptococcal (GAS) pharyngitis.
Pathogenesis (Molecular Mimicry): The hallmark is cross-reactive immunity:
  • Antibodies and CD4+ T cells directed against streptococcal M proteins recognize cardiac antigens (pericardial, myocardial, valvular)
  • Antibody binding activates complement and recruits neutrophils and macrophages
  • T-cell cytokine production activates macrophages within Aschoff bodies (pathognomonic granulomatous lesions in myocardium)
  • Streptococci are completely absent from the lesions - it is purely immune-mediated
Diagnosis - Jones Criteria (major criteria):
  • Carditis (pancarditis - peri-, myo-, endocarditis)
  • Arthritis (migratory polyarthritis, most common manifestation)
  • Sydenham's chorea (involuntary movements)
  • Erythema marginatum (skin rash with clear center)
  • Subcutaneous nodules
Minor criteria: fever, elevated ESR/CRP, prolonged PR interval on ECG. Evidence of preceding GAS infection (positive throat culture or rising ASO titres) required.
Treatment: Penicillin to eradicate GAS; aspirin/NSAIDs for arthritis; corticosteroids for severe carditis.

Rheumatic Heart Disease (RHD)

Definition: Chronic fibrotic valvular disease resulting from repeated or severe RF episodes. RF and RHD remain a major public health problem in low-resource countries.
Key features:
  • Principally affects the mitral valve (mitral stenosis is virtually always due to RHD)
  • Progressive fibrosis and fusion of valve leaflets and chordae tendineae
  • Leads to mitral stenosis (most characteristic), mitral regurgitation, aortic stenosis/regurgitation
  • Tricuspid and pulmonary valves less commonly involved
Complications: Atrial fibrillation, systemic embolism, pulmonary hypertension, infective endocarditis superimposed on damaged valves.
Prevention: Long-term secondary prophylaxis with benzathine penicillin G every 3-4 weeks for those who have had RF, to prevent recurrent episodes.

CONGESTIVE CARDIAC FAILURE (CCF) in Children

Definition: Inability of the heart to pump enough blood to meet the body's metabolic demands, or doing so only at the cost of elevated filling pressures.
Common causes in children:
  • Congenital heart defects (VSD, PDA, AVSD) - most common cause in infancy
  • Rheumatic heart disease
  • Cardiomyopathies
  • Myocarditis
Features in infants (different from adults!):
  • Feeding difficulties, poor weight gain, faltering growth
  • Tachycardia, tachypnea
  • Hepatomegaly (right-sided failure)
  • Diaphoresis (especially during feeding)
  • Pulmonary congestion and wheezing
  • Peripheral edema is less prominent than in adults
Management:
  • Diuretics (furosemide) to reduce preload
  • ACE inhibitors / ARBs to reduce afterload
  • Digoxin (inotrope) in selected cases
  • Treat underlying cause (surgical correction of defect)

HEMATOLOGICAL CONDITIONS

Hemophilia

Definition: X-linked recessive bleeding disorders due to deficiency of clotting factors.
TypeFactor DeficiencyPrevalence
Hemophilia AFactor VIII~80% of cases
Hemophilia B (Christmas disease)Factor IX~20% of cases
Pathophysiology: Both factors are part of the intrinsic coagulation pathway. Deficiency impairs thrombin generation, leading to inadequate clot formation. Primary platelet plug forms normally (bleeding time is normal), but secondary hemostasis (fibrin clot) is defective.
Clinical features (severity depends on factor level):
  • Severe (<1% activity): spontaneous bleeding - hemarthroses (joint bleeding - especially knees, ankles, elbows), deep muscle hematomas, intracranial hemorrhage
  • Moderate (1-5%): bleeding with mild trauma
  • Mild (5-40%): bleeding only with surgery or significant trauma
Diagnosis:
  • Prolonged aPTT (activated partial thromboplastin time)
  • Normal PT, normal bleeding time
  • Specific factor assays confirm type and severity
Treatment:
  • Recombinant Factor VIII (Hemophilia A) or Factor IX (Hemophilia B) replacement
  • Desmopressin (DDAVP) for mild Hemophilia A (releases stored FVIII)
  • Gene therapy is now available for Hemophilia B (Hemgenix - etranacogene dezaparvovec)
  • Emicizumab (bispecific antibody) for Hemophilia A with inhibitors

Thalassemia

Definition: A group of inherited disorders of hemoglobin synthesis caused by mutations reducing or eliminating production of alpha or beta globin chains.
Types:
  • Alpha-thalassemia: deletions of alpha-globin genes (chromosome 16). 4 genes total:
    • 1 gene deleted: silent carrier (normal)
    • 2 genes deleted: alpha-thalassemia trait (mild microcytic anemia)
    • 3 genes deleted: Hemoglobin H disease (moderate hemolytic anemia)
    • 4 genes deleted: Hydrops fetalis (fatal in utero or at birth)
  • Beta-thalassemia: mutations in beta-globin gene (chromosome 11)
    • Beta-thalassemia minor (trait): one abnormal gene; mild microcytic anemia
    • Beta-thalassemia major (Cooley's anemia): both genes abnormal; severe transfusion-dependent anemia starting in first year of life
Pathophysiology: Imbalanced globin chain production → excess unpaired chains precipitate inside RBCs → ineffective erythropoiesis, hemolysis, and iron overload (from transfusions).
Clinical features of Beta-thalassemia major:
  • Severe hemolytic anemia (Hb 3-7 g/dL) requiring regular transfusions
  • Thalassemic facies: frontal bossing, maxillary overgrowth (from expanded bone marrow)
  • Hepatosplenomegaly (extramedullary hematopoiesis)
  • Jaundice
  • Growth retardation
  • Iron overload: cardiac failure, cirrhosis, endocrine dysfunction (hypogonadism, diabetes)
  • "Hair-on-end" appearance on skull X-ray (marrow expansion)
Diagnosis: Peripheral smear (microcytic, hypochromic RBCs, target cells, nucleated RBCs), Hb electrophoresis (elevated HbA2 and HbF in beta-thal minor), low serum ferritin in early iron deficiency vs. high ferritin in thalassemia.
Treatment:
  • Regular blood transfusions + iron chelation (deferoxamine, deferasirox)
  • Hydroxurea (increases HbF)
  • Allogeneic hematopoietic stem cell transplantation (curative)
  • Gene therapy emerging

Anemia

Definition: Reduction in RBC mass or hemoglobin concentration below normal for age and sex. In clinical practice: Hb <13 g/dL in adult males, <12 g/dL in adult females, <11 g/dL in children.
Classification by MCV (RBC size):
TypeMCVCauses
Microcytic<80 fLIron deficiency (most common), thalassemia, anemia of chronic disease, sideroblastic
Normocytic80-100 fLHemolysis, aplastic anemia, acute blood loss, renal failure
Macrocytic>100 fLB12/folate deficiency (megaloblastic), liver disease, hypothyroidism
Iron Deficiency Anemia (most common worldwide):
  • Stages: depleted stores → impaired erythropoiesis → frank anemia
  • Causes: poor intake (infants, toddlers, adolescents), chronic blood loss, malabsorption
  • Features: fatigue, pallor, koilonychia (spoon nails), pica, glossitis
  • Lab: low serum ferritin (earliest), low serum iron, high TIBC, low MCV
  • Treatment: oral ferrous sulfate; treat underlying cause
Megaloblastic (B12/Folate deficiency):
  • Impaired DNA synthesis → large RBCs, hypersegmented neutrophils
  • B12 deficiency also causes subacute combined degeneration of spinal cord (neurological)
  • Treatment: B12 injections (if pernicious anemia) or oral supplementation; folate replacement

Leukemia

Definition: Malignant neoplasms of hematopoietic precursors characterized by uncontrolled proliferation of abnormal white blood cells.
Classification:
TypePeak AgeFeatures
ALL (Acute Lymphoblastic Leukemia)Children 2-5 yearsMost common childhood cancer. B-cell more common.
AML (Acute Myeloid Leukemia)AdultsDe novo or secondary to MDS/chemotherapy
CLL (Chronic Lymphocytic Leukemia)ElderlyIndolent; smudge cells on smear
CML (Chronic Myeloid Leukemia)Adults 30-50 yearsPhiladelphia chromosome (t9;22), BCR-ABL1
ALL - key details (most relevant pediatric):
  • Presentation: bone pain, fatigue, pallor, fever, bleeding, lymphadenopathy, hepatosplenomegaly, CNS involvement (headache, cranial nerve palsies)
  • Peripheral smear: lymphoblasts; bone marrow >20% blasts
  • Good prognostic features: age 1-9 years, WBC <50,000, hyperdiploidy, TEL-AML1 translocation
  • Treatment: multi-agent chemotherapy (induction → consolidation → maintenance), CNS prophylaxis; overall cure rate ~85-90% in children
CML:
  • Philadelphia chromosome: t(9;22) → BCR-ABL1 fusion → constitutively active tyrosine kinase
  • Treatment: imatinib (tyrosine kinase inhibitor) - revolutionized CML management

Idiopathic Thrombocytopenic Purpura (ITP)

Also called Immune Thrombocytopenic Purpura
Definition: Autoimmune condition characterized by production of IgG antibodies against platelet surface antigens (typically GPIIb/IIIa or GPIb/IX), leading to platelet destruction by splenic macrophages.
Types:
  • Acute ITP (childhood): Most common in children aged 2-6 years. Often follows viral infection or vaccination by 1-4 weeks. Usually self-limiting (resolves within 6 months in 80%).
  • Chronic ITP (adult): More common in women. Persists >12 months. Requires treatment.
Clinical features:
  • Petechiae and purpura (small, flat, painless)
  • Easy bruising
  • Mucosal bleeding (gum bleeds, epistaxis)
  • Menorrhagia in adult women
  • Risk of intracranial hemorrhage (rare, <1%, but serious)
  • Spleen is normal or minimally enlarged (important distinguishing point from other causes)
  • No lymphadenopathy, no fever, no hepatosplenomegaly (these suggest another diagnosis)
Diagnosis:
  • Isolated thrombocytopenia on CBC (platelets <100,000/µL)
  • Normal or increased megakaryocytes on bone marrow biopsy (increased production but increased destruction)
  • Exclusion of other causes (lupus, HIV, drug-induced, etc.)
  • Peripheral smear: large platelets (thrombocytopenia with normal-sized or large platelets)
  • No fragmented RBCs (distinguishes from TTP/HUS)
Management:
  • Mild (platelets >30,000, no significant bleeding): observe (especially children with acute ITP)
  • Active bleeding or platelets <20,000: IVIG (fastest response, raises platelets within 24-48h), IV methylprednisolone
  • Chronic ITP: oral prednisolone; rituximab (anti-CD20); thrombopoietin receptor agonists (eltrombopag, romiplostim)
  • Splenectomy: reserved for refractory cases (removes the primary site of platelet destruction and antibody production); ~60-70% durable response

Hodgkin Lymphoma (HL)

Definition: A malignant lymphoma characterized by the presence of Reed-Sternberg (RS) cells - large, binucleated or multinucleated cells with prominent "owl-eye" nucleoli - derived from germinal center B cells.
Epidemiology: Bimodal age distribution - peak in young adults (15-35 years) and again in older adults (>55 years).
Classification (WHO/Lukes-Butler):
SubtypeFrequencyFeatures
Nodular sclerosis~70%Most common; young adults; lacunar RS cells; collagen bands
Mixed cellularity~25%Older adults, HIV patients; classic RS cells
Lymphocyte-rich~5%Good prognosis
Lymphocyte-depletedRareWorst prognosis; elderly/HIV
Nodular lymphocyte predominant~5%LP ("popcorn") cells, not classic RS; CD20+
Clinical features:
  • Painless cervical or supraclavicular lymphadenopathy (most common presentation)
  • Mediastinal involvement common (especially nodular sclerosis)
  • B symptoms: fever, night sweats, weight loss >10% in 6 months (poor prognosis)
  • Alcohol-induced pain at nodal sites (characteristic but rare)
  • Pel-Ebstein fever: cyclic fever pattern (classic but uncommon)
  • Hepatosplenomegaly
  • Pruritis
Staging (Ann Arbor):
  • I: Single lymph node region
  • II: Two or more regions on same side of diaphragm
  • III: Both sides of diaphragm
  • IV: Disseminated, extranodal (liver, bone marrow)
Diagnosis:
  • Excisional lymph node biopsy (gold standard)
  • Reed-Sternberg cells: CD15+, CD30+, CD45- (negative for common leukocyte antigen)
  • CT of chest/abdomen/pelvis for staging; PET-CT now standard
Treatment:
  • Early stage (I-II, favorable): ABVD chemotherapy ± radiation
  • Advanced (III-IV) or unfavorable: ABVD or escalated BEACOPP
  • Excellent prognosis overall - ~85-90% cure rate for early stage
  • Relapsed/refractory: brentuximab vedotin (anti-CD30), pembrolizumab, autologous stem cell transplant

Non-Hodgkin Lymphoma (NHL)

Definition: A heterogeneous group of lymphoid malignancies (B-cell, T-cell, or NK-cell origin) that do not have Reed-Sternberg cells.
Key differences from Hodgkin lymphoma:
FeatureHodgkinNon-Hodgkin
RS cellsPresent (defining)Absent
SpreadContiguous, orderlyNon-contiguous, unpredictable
Extranodal diseaseUncommonCommon
Mediastinal massCommon (NS type)Less common
Waldayer's ring/gutRarelyCommonly involved
Bone marrowRarelyCommonly involved
Common NHL types:
B-cell NHL:
  • Diffuse Large B-cell Lymphoma (DLBCL): Most common NHL overall (~30%). Aggressive, but potentially curable with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone)
  • Follicular Lymphoma: Indolent; t(14;18) - BCL2 overexpression (antiapoptotic). Not curable but long survival
  • Burkitt Lymphoma: Highly aggressive; t(8;14) - MYC overexpression. "Starry sky" pattern on histology. Associated with EBV (endemic form). Presents in jaw (African children) or abdomen
  • Marginal Zone Lymphoma (MALT): Associated with H. pylori gastritis; can regress with H. pylori eradication
  • Mantle Cell Lymphoma: t(11;14) - cyclin D1 overexpression. Aggressive, CD5+
T-cell NHL:
  • Anaplastic large cell lymphoma
  • Peripheral T-cell lymphoma NOS
  • Adult T-cell leukemia/lymphoma (HTLV-1 associated)
Clinical features:
  • Painless lymphadenopathy (may be widespread or localized)
  • Extranodal involvement common: GI tract, skin, CNS, bone marrow
  • B symptoms (fever, night sweats, weight loss) indicate high-grade disease
  • Cytopenias from bone marrow involvement
Diagnosis:
  • Lymph node biopsy + immunohistochemistry (CD20, CD3, CD10, BCL2, BCL6, Ki-67, etc.)
  • Flow cytometry for lymphocyte markers
  • Cytogenetics/FISH for characteristic translocations
  • PET-CT for staging
Treatment:
  • Indolent NHL (follicular): watch-and-wait in asymptomatic cases; rituximab ± chemo when treatment needed
  • Aggressive NHL (DLBCL): R-CHOP x 6 cycles (~60% cure)
  • Burkitt: intensive multi-agent chemo; extremely chemosensitive

Summary Table

ConditionKey HallmarkOne Critical Point
ASDFixed split S2Low endocarditis risk
VSDPansystolic murmurMost common CHD, may close spontaneously
PDAContinuous machinery murmurClose with indomethacin in premature neonates
TOFBoot-shaped heart, tet spellsMost common cyanotic CHD beyond infancy
Rheumatic FeverMolecular mimicry, Aschoff bodiesJones criteria for diagnosis
RHDMitral stenosisVirtually always due to RHD
Hemophilia AProlonged aPTT, normal BTFactor VIII deficiency
ThalassemiaMicrocytic anemia, thalassemic faciesIron overload from transfusions
ITPIsolated thrombocytopeniaOften self-limiting in children
ALLMost common childhood cancer~85-90% cure in children
CMLPhiladelphia chromosome (BCR-ABL)Imatinib is the treatment
Hodgkin HLReed-Sternberg cells (CD15+, CD30+)Bimodal age, excellent prognosis
Non-Hodgkin NHLNo RS cells, extranodal commonR-CHOP for DLBCL
Sources: Robbins & Kumar Basic Pathology (9780323790185); Rosen's Emergency Medicine (9780323757898); Morgan & Mikhail's Clinical Anesthesiology 7e (9781260473797); Robbins, Cotran & Kumar Pathologic Basis of Disease (9780443264528); Fuster and Hurst's The Heart 15e (9781264257560)
This is a shared conversation. Sign in to Orris to start your own chat.